Clinical Research Associate 2 - Oncology

AbbVie (ABBV) stock: FDA approves new Parkinson's drug Juvmo. AbbVie (ABBV) stock: FDA approves Juvmo, a new Parkinson's disease drug, ahead of its October 2026 U.S. launch. By Trader Edge September 28, 2026 3 Mins Read Tldr. * AbbVie received FDA approval for Juvmo (tavapadon), a new Parkinson's disease treatment. * Juvmo is the first selective D1/D5 receptor agonist approved for the condition. * The drug is taken once daily and can be used with or without levodopa. * Approval was based on Phase 3 TEMPO trial data showing improved daily functioning. * AbbVie plans to launch Juvmo in the U.S. in October 2026. AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA approved Juvmo, a new drug for Parkinson's disease. Juvmo is the brand name for tavapadon. It's a once daily tablet designed to help control motor symptoms in adults with Parkinson's. This approval matters because Juvmo works differently than existing options. It's the first and only selective D1/D5 receptor agonist approved for Parkinson's disease. Most current dopamine agonists target D2/D3 receptors instead. Those drugs can come with tolerability issues that limit how doctors use them. AbbVie says Juvmo gives doctors a new tool. It can be taken alone or alongside oral levodopa, the standard treatment for Parkinson's. Why this approval stands out. Levodopa remains the backbone of Parkinson's treatment. But many patients need higher and more frequent doses as the disease progresses. That escalation isn't free. It can lead to complications like dyskinesia, which are involuntary movements that affect quality of life. According to AbbVie, about 70% of Parkinson's patients see their levodopa dose increased within the first year of treatment. Juvmo may help slow that trend. In the TEMPO clinical trial program, results looked promising. After 85 weeks on Juvmo, 93% of participants hadn't needed to increase their levodopa dose. For patients with early Parkinson's, 94% hadn't started levodopa at all after the same period. Those numbers come from the open label extension phase of the trial, called TEMPO-4. What the trial data showed. The TEMPO-1 study measured daily living scores using a standard Parkinson's rating scale. Patients on Juvmo saw a 22 to 23% improvement compared to baseline. The placebo group, meanwhile, got worse by 12%. That gap was statistically significant across both tested doses. In TEMPO-3, which looked at patients already on levodopa, Juvmo increased "on" time without troublesome dyskinesia. Patients gained 1.7 hours of on time versus 0.6 hours for placebo. "Off" time, when symptoms return, also dropped more sharply with Juvmo. Patients saw a 1.9 hour reduction compared to 0.9 hours for placebo. Side effects were mostly mild to moderate. The most common included nausea, headache, dizziness, and fatigue. For patients combining Juvmo with levodopa, dyskinesia and hallucinations also showed up as common side effects. AbbVie noted the overall safety profile was described as favorable. Roopal Thakkar, AbbVie's chief scientific officer, called this the first major dopaminergic breakthrough for Parkinson's in decades. That's a notable claim given how long the treatment landscape has stayed static. Outside voices echoed the sentiment. Hubert Fernandez, a neurologist at Cleveland Clinic who worked on the TEMPO trials, said the approval gives doctors more flexibility to tailor treatment. The Michael J. Fox Foundation also weighed in. Its chief scientist, Brian Fiske, called the approval an important step in building out treatment options for Parkinson's patients. AbbVie confirmed Juvmo will be available to patients in the U.S. starting in October 2026. That's just weeks away from today's announcement. Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions - all in one powerful platform. Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount. Limited Time Offer Get 3 free stock ebooks. Discover top-performing stocks in AI, Crypto, and Technology with expert analysis. * Top 10 AI Stocks - Leading AI companies * Top 10 Crypto Stocks - Blockchain leaders * Top 10 Tech Stocks - Tech giants Futures & Crypto Trader | Sharing charts, strategies, & mindset tips to help you level up | Not Financial Advice Follow on X @Pro_Trader_Edge September 28, 2026

The US Food and Drug Administration has approved AbbVie's JUVMO (tavapadon) for treating Parkinson's disease in adults. JUVMO is the first selective D1/D5 receptor agonist approved for this condition, offering a different approach from existing dopamine agonists that primarily target D2/D3 receptors. The once-daily treatment can be taken with or without levodopa therapy. Approval was based on the Phase 3 TEMPO clinical trial programme, which demonstrated significant improvements in daily functioning and increased "on" time without troublesome dyskinesia. In trials, 93% of participants on JUVMO with levodopa for 85 weeks did not increase their levodopa dose, whilst 94% of early-stage patients did not initiate levodopa therapy. Common side effects included nausea, headache, dizziness and fatigue. AbbVie expects to make JUVMO available in the US in October 2026.

ADARx Pharmaceuticals announces pricing of upsized $446.3 million initial public offering. SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) - ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by ADARx. The gross proceeds to ADARx from the offering, before deducting underwriting discounts and commissions and offering expenses payable by ADARx, are expected to be approximately $446.3 million. In addition, the underwriters have a 30-day option to purchase up to an additional 3,937,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market on September 25, 2026, under the ticker symbol "ADRX." The offering is expected to close on September 28, 2026, subject to the satisfaction of customary closing conditions. J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are acting as lead book-running managers for the offering. LifeSci Capital is acting as a book-running manager for the offering. Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 24, 2026. Copies of the registration statements can be accessed through the SEC's website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected] and [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; or UBS Securities LLC, Attention: Equity Syndicate, 11 Madison Avenue, New York, NY 10010 or by email at [email protected]. In addition, AbbVie has agreed to purchase, in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), a number of shares of ADARx's common stock that would result in AbbVie owning approximately 4.9% of ADARx's outstanding shares of common stock following the closing of the initial public offering and the concurrent private placement, at a price of $17.00 per share; provided, however, that in no event would AbbVie purchase more than $100.0 million in shares of common stock. The aggregate gross proceeds to ADARx from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions, placement agent fees and other offering and private placement expenses payable by ADARx, are expected to be approximately $535.2 million, excluding any exercise of the underwriters' option to purchase additional shares of common stock. The concurrent private placement is also scheduled to close on September 28, 2026, subject to the satisfaction of customary closing conditions. The closing of the concurrent private placement is contingent and conditioned upon consummation of the initial public offering. However, the closing of the initial public offering is not contingent on the consummation of the concurrent private placement. This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act. About ADARx Pharmaceuticals ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. We have developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology. Forward-Looking Statements The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as "believe," "can," "estimate," "expect," "intend," "may," "plans," "should," "seeks," or "will," or similar expressions which concern ADARx's strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to ADARx's expected gross proceeds from the initial public offering and concurrent private placement, the expected date for ADARx's common stock to begin trading on the Nasdaq Global Select Market and the expected closing of the initial public offering and concurrent private placement. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. ADARx's expectations, beliefs and projections are expressed in good faith and ADARx believes there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. ADARx undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.